Want to create an interactive transcript for this episode?
Podcast: Company Interviews
Episode: Marvel Biosciences (TSXV:MRVL) - Novel Treatment For Social Withdrawal Shows Rapid Results
Description: Interview with Dr. Mark Williams, President & CSO, and J. Roderick Matheson, Director & CEO of Marvel Bioscience Corp.Recording date: 16th March 2026Marvel Biosciences is advancing MB-204, a first-in-class treatment for social withdrawal conditions across autism spectrum disorder, depression, and Alzheimer's disease. The clinical-stage biotechnology company targets an underserved therapeutic area affecting millions globally, with autism prevalence reaching one in 36 children in the United States and depression impacting one in eight adults currently on antidepressants. The addressable market spans hundreds of billions of dollars in healthcare costs and lost productivity.The compound is based o...